These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
352 related items for PubMed ID: 19956851
1. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. Shim J, Kim BH, Kim YI, Kim KY, Hwangbo Y, Jang JY, Dong SH, Kim HJ, Chang YW, Chang R. Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851 [Abstract] [Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. Lin MS, Chen WC, Bai X, Wang YD. J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820 [Abstract] [Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Zang C, Liu H, Posch MG, Waechter M, Facklam M, Fenner MH, Ruthardt M, Possinger K, Phillip Koeffler H, Elstner E. Leuk Res; 2004 Apr; 28(4):387-97. PubMed ID: 15109539 [Abstract] [Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K. Cancer; 2002 Nov 15; 95(10):2243-51. PubMed ID: 12412180 [Abstract] [Full Text] [Related]
5. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma. Yuan J, Takahashi A, Masumori N, Uchida K, Hisasue S, Kitamura H, Itoh N, Tsukamoto T. Urology; 2005 Mar 15; 65(3):594-9. PubMed ID: 15780399 [Abstract] [Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL, Guan YF. Acta Pharmacol Sin; 2005 Jun 15; 26(6):753-61. PubMed ID: 15916743 [Abstract] [Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Eucker J, Sterz J, Krebbel H, Zavrski I, Kaiser M, Zang C, Heider U, Jakob C, Elstner E, Sezer O. Anticancer Drugs; 2006 Aug 15; 17(7):763-9. PubMed ID: 16926626 [Abstract] [Full Text] [Related]
8. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC. Hepatology; 2006 Jan 15; 43(1):134-43. PubMed ID: 16374840 [Abstract] [Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K. Cancer Detect Prev; 2008 Jan 15; 32(3):259-66. PubMed ID: 18789607 [Abstract] [Full Text] [Related]
10. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma. Takashima T, Fujiwara Y, Hamaguchi M, Sasaki E, Tominaga K, Watanabe T, Oshitani N, Higuchi K, Arakawa T. Oncol Rep; 2005 Apr 15; 13(4):601-6. PubMed ID: 15756430 [Abstract] [Full Text] [Related]
11. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats. Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, Nagasue N. J Gastroenterol Hepatol; 2008 Jun 15; 23(6):930-7. PubMed ID: 18565023 [Abstract] [Full Text] [Related]
12. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Kim KR, Choi HN, Lee HJ, Baek HA, Park HS, Jang KY, Chung MJ, Moon WS. Oncol Rep; 2007 Oct 15; 18(4):825-32. PubMed ID: 17786342 [Abstract] [Full Text] [Related]
13. The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Emi M, Maeyama K. Biochem Pharmacol; 2004 Apr 01; 67(7):1259-67. PubMed ID: 15013841 [Abstract] [Full Text] [Related]
14. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo. Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC. Clin Cancer Res; 2008 Jul 01; 14(13):4045-52. PubMed ID: 18593980 [Abstract] [Full Text] [Related]
15. 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibits fibrogenic response in human hepatoma cells. Suk FM, Chen CH, Lin SY, Cheng CJ, Yen SJ, Hung LF, Liu DZ, Liang YC. Toxicol Lett; 2009 May 22; 187(1):22-7. PubMed ID: 19429239 [Abstract] [Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes. Liu J, Xia Q, Zhang Q, Li H, Zhang J, Li A, Xiu R. Shock; 2009 Sep 22; 32(3):317-24. PubMed ID: 19174742 [Abstract] [Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS, Kim KS, Song S, Yun YP, Lee MK, Oh KW, Yoon DY, Hong JT. J Pharmacol Exp Ther; 2003 Nov 22; 307(2):505-17. PubMed ID: 12966153 [Abstract] [Full Text] [Related]
18. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Morosetti R, Servidei T, Mirabella M, Rutella S, Mangiola A, Maira G, Mastrangelo R, Koeffler HP. Int J Oncol; 2004 Aug 22; 25(2):493-502. PubMed ID: 15254749 [Abstract] [Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, Sugawara A, Ishida T, Ohuchi N, Sasano H. Endocr Relat Cancer; 2006 Mar 22; 13(1):233-50. PubMed ID: 16601291 [Abstract] [Full Text] [Related]
20. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I. Breast Cancer Res Treat; 2008 Dec 22; 112(3):437-51. PubMed ID: 18204896 [Abstract] [Full Text] [Related] Page: [Next] [New Search]